This study is a phase 1, open-label, crossover, comparison study to evaluate the safety and
pharmacokinetics (PK) of a single IM administration of 10 mg midazolam using Rafa's
auto-injector compared with seizalam in healthy adults. All subjects will participate in both
study periods which will span 28 days following a pre study screening visit.
Phase:
Phase 1
Details
Lead Sponsor:
Rafa Laboratories
Collaborators:
Joint Project Management Office for Chemical, Biological, Radiological, and Nuclear Medical Ology Bioservices